Future growth expectations in earnings/operating earnings/profits/EPS?

Innova Captab expects 20%+ revenue growth in the coming years driven by capacity ramp-up, expanding product portfolio, and deeper market penetration. EBITDA growth is anticipated to outperform revenue growth due to operating leverage from ramping up Jammu facility and other efficiencies. PAT growth should outpace EBITDA growth as depreciation and financial costs related to new facilities like Jammu are largely fixed and already reflected in the base. Incremental growth is expected to translate into stronger profitability going forward. Despite ongoing investments in capacity and capabi

IN US

Sale is live|00:00:00left today

Innova Captab LtdQ1 FY26Pharmaceuticals & Biotechnology

Innova Captab Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹994P/E: 34.9Market Cap: ₹4.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

No information is provided regarding the same in the latest conference call.

Margin guidance

Category 3

→Innova Captab expects 20%+ revenue growth in the coming years driven by capacity ramp-up, expanding product portfolio, and deeper market penetration.
→EBITDA growth is anticipated to outperform revenue growth due to operating leverage from ramping up Jammu facility and other efficiencies.
→PAT growth should outpace EBITDA growth as depreciation and financial costs related to new facilities like Jammu are largely fixed and already reflected in the base.
→Incremental growth is expected to translate into stronger profitability going forward.
→Despite ongoing investments in capacity and capabilities, margin expansion is projected due to operational leverage and cost capitalization practices for new plants.
→The company remains confident in delivering long-term value with disciplined capital allocation and a solid financial foundation supporting growth ambitions.

3 more insights locked — sign up free to unlock

Fundraise plans

No information is provided regarding the same in the latest conference call.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Innova Captab Limited. However, the following points provide some relevant insights related to business growth and demand: - Jammu facility achieved INR 300 crores revenue in FY '26, with a strong ramp-up and expected 20%+ volume growth in FY '27. - The company is confident of maintaining overall 20%+ volume growth at the group level. - Growing demand in both CDMO and Branded Generics segments supports continuing order flow. - Capacity expansions, including the new Baddi plant, are planned to address increasing demand. - Strong R&D pipeline and relationships with front-end marketing partners indicate good visibility on future product orders. - Management emphasized a positive outlook on margin expansion, driven by operational leverage as revenues grow. No specific quantitative figures on order book or pending orders were disclosed in the call excerpt.

Capex plans

Yes

No information is provided regarding the same in the latest conference call.

How does Innova Captab Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Innova Captab Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Innova Captab Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio